Understanding how chemotherapy affects nerve cells to improve treatment outcomes.
Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity
This study is looking into how chemotherapy can cause painful nerve damage and aims to find ways to prevent or ease this side effect, so cancer patients can feel better while still getting their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11060971 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms behind chemotherapy-induced peripheral neuropathy, a painful condition that can limit the effectiveness of cancer treatments. By focusing on sphingosine-1-phosphate (S1P) signaling in sensory neurons, the study aims to identify targeted therapies that can prevent or alleviate this side effect. Using advanced human stem cell models, researchers will explore how changes in S1P signaling contribute to nerve damage caused by chemotherapy. The goal is to develop strategies that enhance patient quality of life while maintaining effective cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing chemotherapy who experience or are at risk of developing peripheral neuropathy.
Not a fit: Patients who are not receiving chemotherapy or those with pre-existing neuropathic conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that reduce nerve damage from chemotherapy, improving the quality of life for cancer patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of S1P signaling in nerve toxicity, suggesting that this approach may lead to effective interventions.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Kroetz, Deanna L — Ohio State University
- Study coordinator: Kroetz, Deanna L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.